Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Treprostinil
Drug ID BADD_D02268
Description Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
Indications and Usage For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Marketing Status approved; investigational
ATC Code B01AC21
DrugBank ID DB00374
KEGG ID D06213
MeSH ID C427248
PubChem ID 6918140
TTD Drug ID D01WUA
NDC Product Code 0703-0696; 0781-3430; 11014-0094; 66302-350; 66302-648; 66302-748; 66302-361; 66302-363; 66302-620; 66302-720; 0703-0676; 43598-646; 43598-647; 66302-302; 66302-325; 66302-616; 66302-362; 0703-0666; 14501-0015; 42023-209; 62332-515; 66302-110; 66302-300; 66302-610; 54893-0024; 43598-649; 62332-514; 62332-517; 66302-102; 66302-206; 66302-732; 58159-041; 68245-0008; 43598-648; 66302-120; 66302-600; 66302-650; 66302-764; 0703-0686; 0781-3420; 0781-3425; 81861-0029; 66302-101; 66302-310; 66302-630; 66302-664; 0781-3427; 42023-206; 66302-105; 66302-640; 42023-207; 62332-516; 66302-632; 66302-716; 42023-208
UNII RUM6K67ESG
Synonyms treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine
Chemical Information
Molecular Formula C23H34O5
CAS Registry Number 81846-19-7
SMILES CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Faeces soft07.01.03.0080.000559%-
Complication associated with device08.07.01.0110.002319%-
Multiple organ dysfunction syndrome08.01.03.0570.000658%
Device related thrombosis08.07.05.001; 24.01.01.0270.000123%-
Anal incontinence07.01.06.029; 17.05.01.0210.000362%
Anaemia of chronic disease01.03.04.0020.000082%-
Cardiac failure chronic02.05.01.0090.000164%-
Chronic respiratory failure14.01.04.005; 22.02.06.0050.000247%-
Cor pulmonale chronic02.05.03.005; 22.06.01.005; 24.08.03.0050.000164%-
Neonatal respiratory distress syndrome18.04.10.003; 22.11.02.0100.000082%-
Pneumothorax spontaneous22.05.02.0070.000082%-
Pulmonary sarcoidosis10.02.06.003; 22.01.01.0230.000280%-
Restrictive pulmonary disease22.01.02.0250.000123%-
Terminal state08.01.03.0790.000082%-
Live birth18.08.02.0070.000082%-
Tracheal stenosis22.04.07.0100.000082%
Right ventricular dysfunction02.04.02.0330.000082%
Acute right ventricular failure02.05.03.0030.000164%-
Weight bearing difficulty15.03.05.0340.000181%-
Portopulmonary hypertension09.01.06.026; 22.06.01.006; 24.08.03.0060.000123%-
Apparent death08.01.03.0620.000082%-
Heart valve incompetence02.07.02.0030.000082%-
Pulmonary hypertensive crisis22.06.01.007; 24.08.03.0070.000164%-
Ventilation perfusion mismatch22.02.07.0180.000403%-
Sensitivity to weather change08.01.03.0770.000280%-
Gastrointestinal polyp haemorrhage07.20.01.011; 16.05.01.008; 24.07.02.0460.000082%-
Pulmonary pain22.12.01.0100.000362%-
Internal haemorrhage24.07.01.0720.000288%-
Fine motor skill dysfunction17.01.02.0200.000280%-
End stage renal disease20.01.03.0190.000164%-
The 13th Page    First    Pre   13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene